TrialHuman vaccines & immunotherapeutics2020

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study.

Victor Romanenko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.